Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06636656 · ClinicalTrials.gov registry record · Phase 2
A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis
A Phase 2 study of Ulcerative Colitis, sponsored by Boehringer Ingelheim.
- Active
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 20
- Study locations
NCT06636656 is a Phase 2 study of Ulcerative Colitis that is active but no longer recruiting, run by Boehringer Ingelheim. The registered enrollment target is 45 participants, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT06636656, a Phase 2 study of Ulcerative Colitis, is active but no longer recruiting, sponsored by Boehringer Ingelheim.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 20
- Study locations
Study Summary
Adults between 18 and 80 years of age with ulcerative colitis can participate in this study. This is a study for people for whom previous treatment was not successful or who stopped previous treatment. The purpose of this study is to find out whether BI 3032950 helps people with ulcerative colitis. This study has 2 parts. In Part A, participants get BI 3032950 as an infusion into a vein every 4 weeks. After 12 weeks, doctors check whether the signs and symptoms of ulcerative colitis have improved. Before the results of this assessment are available, participants move on to Part B and get BI 3032950 as an injection under the skin. Participants whose results show clinical response after 12 weeks can continue treatment with BI 3032950. They get BI 3032950 injections under the skin every 4 weeks for up to 2 years. Participants visit their doctors every 4 weeks. During these visits, the doctors check the signs and symptoms of ulcerative colitis. This includes taking blood and stool samples. Doctors also do endoscopies. This is a procedure that uses a tube with a camera to look inside the body. The doctors also regularly check participants' health and take note of any unwanted effects.
Conditions Studied
Interventions
- DRUG BI 3032950 intravenous (Part A)
- DRUG BI 3032950 subcutaneous (Part B)
Study Locations (20)
Other
- UZ Leuven - Leuven
- CHC MontLegia - Liège
- Hepato-Gastroenterologie HK, s.r.o. - Hradec Králové
- ISCARE a.s. - Prague
- Centrum Medyczne Plejady - Krakow
- Medrise Sp. z o.o. - Lublin
Florida
- Clinical Research of Osceola - Kissimmee
- Florida Research Institute - Lakewood Rch
- University of Miami - Miami
- Reliant Medical Research - Miami
Texas
- Texas Digestive Disease Consultants - Cedar Park
- Baylor College of Medicine - Houston
Washington
- University of Washington - Seattle
- Digestive Health Specialists - Tacoma
Arizona
- One of a Kind Clinical Research Center - Scottsdale
Colorado
- Peak Gastroenterology Associates - Colorado Springs
Illinois
- Illinois Gastroenterology Group - Gurnee - Gurnee
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2024-12-11 |
| Est. Completion | 2028-02-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06636656
The ClinicalTrials.gov registry entry for NCT06636656 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (98% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 2 interventions - of which BI 3032950 intravenous (Part A) is the first listed.
NCT06636656 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT06636656 about?
NCT06636656 is a clinical study titled "A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis". Adults between 18 and 80 years of age with ulcerative colitis can participate in this study. This is a study for people for whom previous treatment was not successful or who stopped previous treatment. The purpose of this study is to find out whether BI 3032950 helps people with ulcerative colitis. ...
What is the current status of trial NCT06636656?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2024-12-11. Estimated completion is 2028-02-29.
What conditions does trial NCT06636656 study?
This clinical trial studies the following conditions: Ulcerative Colitis.
What interventions are being tested in trial NCT06636656?
The interventions under investigation include: BI 3032950 intravenous (Part A) (DRUG), BI 3032950 subcutaneous (Part B) (DRUG).
Who is sponsoring clinical trial NCT06636656?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06636656 being conducted?
This trial has 20 study locations across Arizona, Colorado, Florida, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
RECRUITING · Phase 2
-
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
Treatment of UC With Novel Therapeutics
RECRUITING · Phase 2
-
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
RECRUITING · Phase 2
-
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.